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New paradigms in the management of osteoarthritis patients with hypertensionEpidemiologic data suggest that approximately 30% of adults in
Western countries are affected by musculoskeletal conditions1.
Osteoarthritis (OA) is the most common and consequential muscu-
loskeletal condition in terms of impact on physical function, health
care costs, and societal burden. OA is second only to ischemic heart
disease as a cause of work disability in men aged 50 years and
accounts for up to 3% of total years of living with disability, making
it the eighth leading nonfatal burden of disease worldwide1.
Because OA is directly related to age and lifestyle factors (e.g.,
obesity, history of sports-related joint injury, lack of physical
activity), the prevalence is expected to grow substantially over
the next several decades as the global population ages and the
“Western” lifestyle becomes more common.
Given the tremendousdand growingdburden imposed by the
disease, considerable efforts have been directed toward addressing
how best to manage the signs and symptoms of OA. A symposium,
held during the Osteoarthritis Research Society International
(OARSI) 2009 World Congress on Osteoarthritis in Montreal,
Quebec, Canada, addressed the current recommendations for the
management of OA, the prevalence and impact of comorbidities
on the patient, particularly hypertension (HTN) and cardiovascular
disease (CVD), and current and future paradigms for optimizing
treatment of OA to maximize symptomatic relief while minimizing
the risks imposed by therapy.
Along with nonpharmacologic treatment, the current OARSI
recommendations suggest using acetaminophen as ﬁrst-line
systemic pharmacotherapy for mild-to-moderate pain in patients
with knee or hip OA. However, recent data suggest both evidence
for diminishing analgesic efﬁcacy and increasing potential long-
term harm of this agent2–5. Nonsteroidal anti-inﬂammatory drugs
(NSAIDs), usually combined with a proton pump inhibitor, and
cyclooxygenase 2 (COX-2) selective inhibitors represent another
option for the symptomatic treatment of OA; among patients
with severe or refractory pain, the use of intra-articular agents
(e.g., glucocorticoids, hyaluronates) and opioids may be considered.
Notably, treatment choices in OA should not be driven purely by
their efﬁcacy in providing symptomatic relief; the provider must
consider the potential adverse effects of the treatment as well as
the values and preferences of the patient. Patients with OA
frequently have one or more comorbid conditions, including HTN
and CVD, gastrointestinal (GI) disorders, endocrine disorders (e.g.,
type II diabetes mellitus), and respiratory disease (e.g., chronic
obstructive lung disease), and chronic kidney disease6. Among CV
and renal comorbidities, patients with OA are more likely to have
HTN (40% vs 25%), diabetes (11% vs 6%), high total cholesterol
(32% vs 24%), and renal impairment (37% vs 27%) compared with
the unaffected population7. Moreover, while patients with OA are1063-4584/$ – see front matter  2010 Osteoarthritis Research Society International. Pu
doi:10.1016/j.joca.2010.04.001not only more likely to have GI disorders, the very agents that are
used for symptomatic managementdNSAIDsdconfer substantial
increases in GI risk.
As a result of these factors, pharmacologic treatment for OA
should be chosen with a careful eye on the impact of therapy on
CV and GI risk. Indeed, current recommendations acknowledge
the potential impact of NSAIDs and COX-2 inhibitors on CV risk
and recommend caution when these agents are used in patients
with established CVD or CV risk factors2. Beyond imposing
increased CV risk directly through elevating blood pressure (BP)8,
it is also clear that these agentsmay interferewith antihypertensive
therapy, especially agents that act on the renin-angiotensin-aldo-
sterone system9. Although less well appreciated than the CV effects
of NSAIDs and COX-2 inhibitors, there is increasing evidence sug-
gesting that acetaminophen is also linked with a substantially
increased risk for HTN in both men10 and women5.
These data have prompted a continued search for agents to
provide symptomatic relief for OA and other musculoskeletal
conditions with improved CV risk proﬁles. In part, BP is regulated
by vascular tone, which is in turn regulated by the interaction
between nitric oxide (NO) and the endothelium. The demonstrated
role of NO in BP control has received considerable attention as the
potential basis for new therapeutic modalities. In particular, estab-
lished agents have been linked to a NO-donating moiety, gener-
ating “NO-donating” therapeutics that provide the beneﬁts of the
base molecule (e.g., an NSAID) while also releasing NO to coun-
teract the potential adverse effects of the original molecule11,12. In
terms of NSAIDs, NO derivatives of aspirin, diclofenac, ﬂurbiprofen,
ibuprofen, and naproxen have been developed to date.
Naproxcinod, which consists of naproxen joined via a linker to
NO, is currently in late clinical development. This agent has been
shown to rapidly release NO in pharmacokinetic models13; in
animal models, it has been shown to reduce BP in spontaneously
hypertensive rats, attenuate renovascular and L-NAME HTN, and
protect against ischemia-reperfusion injury14. In human studies,
naproxcinod appears to have a considerably lower liability for
increasing BP as measured by 24-h ambulatory BP monitoring.
The early promise that naproxcinod may reduce the risk for GI
events has not yet been borne out in clinical trials. A phase 2
randomized, placebo controlled trial evaluating the GI safety and
efﬁcacy of naproxcinod vs naproxen in patients with OA did not
show a signiﬁcant difference between naproxcinod and naproxen
in terms of the primary endpoint of 6-week endoscopic gastroduo-
denal ulcer incidence15. However, within the prespeciﬁed
secondary endoscopic end points naproxcinod was associated
with signiﬁcantly less mucosal injury than naproxen when scored
on the Lanza scale, or in terms of the number of erosions and ulcersblished by Elsevier Ltd. All rights reserved.
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number of erosions in stomach and duodenum combined, stomach
alone or duodenum alone. There was also an improved within
subject difference for reﬂux and abdominal pain with naproxcinod
vs naproxen15. While naproxcinod has shown a trend in the reduc-
tion of endoscopic ulcers when compared to naproxen, more
studies need to be conducted.
Together, the data and surrounding discussion in this sympo-
sium represent the current state-of-the-art in the treatment and
management of HTN and CV risk in patients with OA. Future advan-
cesdparticularly regarding NO-donating NSAIDsdpromise to
simplify the management of these patients and, potentially, reduce
the CV risks associated with these agents while providing adequate
symptomatic relief.
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